Current Status and Future Perspective of Stenting for Symptomatic Intracranial Atherosclerotic Disease: A Meta-Analysis

Table 1

Characteristics of the RCTs, comparing PTAS plus medical therapy with medical therapy alone.

	Participants	Follow-up	Eligibility criteria	Stenosis rate	Stenosis location	Primary end point
SAMMPRIS	451	32.4 months	TIA or nondisabling stroke within 30 days	70%–99%	Major intracranial arteries	Any stroke or death, myocardial infarction, and any major hemorrhage
VISSIT	111	1 year	Hard TIA or stroke within the past 30 days	70%–99%	Intracranial internal carotid, middle cerebral, intracranial vertebral, or basilar arteries	Any stroke or death, hard TIA, NIHSS, and mRS scores
VAST		3 years	Vertebrobasilar TIA or minor ischemic stroke in the previous 6 months	≥50%	Intracranial vertebral arteries	Vascular death, myocardial infarction, or any stroke

VAST included 115 patients but only 19 of them were located in intracranial vertebral artery; SAMMPRIS: Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis; VISSIT: Vitesse Intracranial Stent Study for Ischemic Stroke Therapy. VAST: Vertebral Artery Stenting Trial; TIA: transient ischemic attack; NIHSS: National Institute of Health Stroke Severity Scale; mRS: modified Rankin Scale.